International Journal of Clinical Research

Objective To analyze the value of implementing rabelol assisted magnesium sulfate treatment in patients with preeclampsia. Methods A total of 69 patients with preeclampsia admitted to our hospital from March 2022 to March 2023 were randomly divided into a control group of 35 cases and an observation group of 34 cases. The two groups were treated with conventional magnesium sulfate therapy and labelol assisted magnesium sulfate therapy, respectively. The blood pressure indicators (systolic and diastolic blood pressure), adverse maternal and infant outcomes (postpartum infection, postpartum hemorrhage, placental abruption, neonatal asphyxia), and incidence of complications (uterine contractions, cervical lacerations, and eclampsia) were compared between the two groups. Results Compared with the control group, the observation group had lower systolic and diastolic blood pressure, lower incidence of adverse maternal and infant outcomes, and lower incidence of complications, with statistical significance (P<0.05). Conclusion The application value of Labelol assisted magnesium sulfate treatment in patients with preeclampsia is high, which effectively improves blood pressure indicators, reduces the incidence of adverse maternal and infant outcomes, reduces complications, and has high treatment safety. It has promotional value.

Labelol; Magnesium sulphate; Treatment; Pih